Text Size

Treatment of Patients With Nocturia (Non-PK Study)

This study has been completed.
Sponsor:
Information provided by:
Serenity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00937378
First received: July 9, 2009
Last updated: December 8, 2010
Last verified: December 2010
History of Changes
  Purpose

The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.


Condition Intervention Phase
Nocturia
 Drug: SER120
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)

Further study details as provided by Serenity Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Number of nocturic episodes [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of nights with less than or equal to one nocturic episode [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment: 326
Study Start Date: June 2009
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SER120 Drug: SER120
Nasal Spray, once a day

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and Female 50 years or older
  • Nocturia of 6 or more months duration averaging 2 episodes or more per night

Exclusion Criteria:

  • CHF
  • Diabetes
  • Diabetes Insipidus, Renal Insufficiency, Hepatic Insufficiency
  • Incontinence
  • Illness requiring steroids
  • Current or past urologic malignancy
  • Nephrotic Syndrome
  • Unexplained pelvic masses
  • Urinary bladder neurological dysfunction
  • Urinary bladder surgery or radiotherapy
  • Sleep Apnea
  • Pregnant or breast feeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00937378

Locations
United States, New York
University Urology Associates
New York, New York, United States, 10016
Sponsors and Collaborators
Serenity Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Linda Cheng, Serenity Pharmaceuticals, LLC
ClinicalTrials.gov Identifier: NCT00937378     History of Changes
Other Study ID Numbers: SPC-SER120-DB2-200902
Study First Received: July 9, 2009
Last Updated: December 8, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Nocturia
Urological Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on May 22, 2013